glp 1 stock price Novo Nordisk (NOVOB) Faces a Tougher Year After Share-Price Surge Generic GLP-1 drugs may help

Pharm Stat (2011) 10(2):15061

Key Players in the GLP-1 Drugs Market Novo Nordisk has been at the forefront of GLP-1 drug development

Non-prescription and compounded peptides such as BPC-157, CJC-1295/Ipamorelin, AOD-9604, and MOTS-c are not FDA-approved for weight loss and lack the same regulatory oversight and clinical safety data as the GLP-1 drugs in the table above, which is why they should only be used under the guidance of a licensed medical provider who can order lab work, personalize dosing, and monitor for side effects throughout treatment

Study found that increasing endogenous and exogenous intestinal SCFAs can stimulate intestinal endocrine cells to secrete GLP-1 and PYY by binding to GPR41 and GPR43 (Tian et al., 2024)